Key Points
- Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
- Use system-specific risk tools to guide testing and disposition.
- Order high-yield tests first; escalate imaging when indicated.
- Start evidence-based initial therapy and reassess frequently.
Algorithm
- Primary survey and vitals; IV access and monitors.
- Focused history/physical; identify red flags and likely etiologies.
- Order system-appropriate labs and imaging (see Investigations).
- Initiate guideline-based empiric therapy (see Pharmacology).
- Reassess response; arrange consultation and definitive management.
Clinical Synopsis & Reasoning
For Acute Angle Closure Glaucoma, frame the differential by acuity and pathophysiology, then align diagnostics to the leading hypotheses. Prioritize stabilization while obtaining high‑yield studies such as CBC (Baseline hematology), BMP (Electrolytes/renal). Incorporate bedside imaging and targeted labs to define severity and identify complications; synthesize results with clinical trajectory to refine the working diagnosis and disposition needs.
Treatment Strategy & Disposition
Initiate disease‑directed therapy alongside supportive care, titrating to objective response. Pharmacologic options commonly include Analgesia/Antipyretics. Use validated frameworks (e.g., Initial Medication Set (Example)) to guide escalation and site of care. Address precipitating factors, de‑escalate empiric therapies with data, and arrange follow‑up for monitoring and risk‑factor modification; admit patients with instability, high risk of deterioration, or needs for close monitoring.
Epidemiology / Risk Factors
- Risk factors vary by condition and patient profile
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| CBC | Baseline hematology | Abnormal counts | |
| BMP | Electrolytes/renal | Derangements |
Initial Medication Set (Example)
| Class | Example |
|---|---|
| Beta blocker (topical) | Timolol |
| Alpha agonist (topical) | Brimonidine |
| Carbonic anhydrase inhibitor | Dorzolamide (topical) or acetazolamide (systemic) |
| Miotic (after IOP falls) | Pilocarpine |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Acetazolamide (IV/PO) | Carbonic anhydrase inhibition | Hours | Lower IOP quickly | Metabolic acidosis; avoid in sulfa allergy |
| Timolol (gtt) | β-blocker (topical) | Minutes | Reduce aqueous production | Bradycardia |
| Prednisolone acetate (gtt) | Topical steroid | Hours | Reduce inflammation | ↑ IOP |
| Pilocarpine (gtt after IOP lowered) | Muscarinic agonist | Minutes | Facilitate outflow | Miosis; use after IOP ↓ |
| Apraclonidine/Brimonidine (gtt) | α2 agonist | Minutes | Reduce aqueous production | Dry mouth |
Prognosis / Complications
- Prognosis depends on severity, comorbidities, and timeliness of care
Patient Education / Counseling
- Explain red flags and when to seek emergent care.
- Reinforce medication adherence and follow-up plan.
Notes
Avoid acetazolamide in sulfa allergy with caution and severe renal failure. Check for precipitating meds (anticholinergics, sympathomimetics).